In one paragraphArticle in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Mohit TyagiDepartment of Medicinal Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.ORCID 0000-0003-1211-629X Vasanthanathan PoongavanamDepartment of Chemistry for Life Sciences, Uppsala University, Box 576, Uppsala 751 23, Sweden.ORCID 0000-0002-8880-9247 Stefanie ZichDepartment of Medicinal Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.
Marika LindhagenEarly Product Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.
Ioannis AsproudisEarly Product Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.
Okky Dwichandra PutraEarly Product Development, Pharmaceutical Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.ORCID 0000-0002-6968-1858 Jie YangDepartment of Chemistry for Life Sciences, Uppsala University, Box 576, Uppsala 751 23, Sweden.
Zackary J R AshworthDepartment of Chemistry for Life Sciences, Uppsala University, Box 576, Uppsala 751 23, Sweden.ORCID 0000-0002-3690-3856 Anna GuadagniDepartment of Medicinal Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.ORCID 0009-0003-4092-3790 Luca J HagemeyerDepartment of Chemistry for Life Sciences, Uppsala University, Box 576, Uppsala 751 23, Sweden.ORCID 0009-0000-6648-0420 Alessandro OlivaDepartment of Chemistry for Life Sciences, Uppsala University, Box 576, Uppsala 751 23, Sweden.
Peter SjöDrugs for Neglected Diseases Initiative (DNDi), 15 Chemin Louis Dunant, Geneva 1202, Switzerland.ORCID 0000-0002-6768-0536 Stefan SchiesserDepartment of Medicinal Chemistry, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Mölndal 431 83, Sweden.ORCID 0000-0002-8668-2844 Jan KihlbergDepartment of Chemistry for Life Sciences, Uppsala University, Box 576, Uppsala 751 23, Sweden.ORCID 0000-0002-4205-6040 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Macrocycles are a highly interesting modality to modulate difficult-to-drug targets, but often reside in chemical space where obtaining sufficient cell permeability and solubility is challenging. We have determined permeability across Caco-2 cells, aqueous solubility and log
Indexed as
Cell Membrane PermeabilityMacrocyclic CompoundsCaco-2 CellsCrystallography, X-RayHumansHydrogen BondingMagnetic Resonance SpectroscopyModels, MolecularMolecular ConformationSolubilityMacrocyclic Compounds
Identifiers
PMID42329245
PMCPMC13370866
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390